Developing the next generation of biotherapeutics
Affimer® technology is a novel class of biotherapeutic based on a naturally occurring human protein called Stefin A.
Avacta is building a pipeline of clinically differentiated cancer immunotherapies leveraging the key benefits of Affimer® technology. Our aim is to extend the benefits of cancer immunotherapies to all patients, including those who do not experience a durable response to current single immune checkpoint inhibitors.
The Affimer® platform is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs a